European Commission approves avelumab plus axitinib combination for the first-line treatment of advanced kidney cancer
Based on the findings from the pivotal phase III JAVELIN [...]
The effect of antibiotic use on outcomes with kidney cancer drug treatments
A recent study has looked at the use of antibiotics [...]
ESMO 2019: First-line avelumab plus axitinib in sarcomatoid kidney cancer – results from JAVELIN Renal 101
Results from the JAVELIN Renal 101 study to evaluate avelumab [...]
ESMO 2019: Avelumab plus axitinib in patients who had not had nephrectomy
Results from a post-hoc analysis of JAVELIN-Renal 101 in patients [...]
ESMO 2019: First in human study of HIF-2α inhibitor in patients with advanced kidney cancer
Results from the first in human study of the HIF-2α [...]
ESMO 2019: Results from JAVELIN-Renal 101 trial for sarcomatoid kidney cancer
Results from the JAVELIN-Renal 101 clinical trial to assess avelumab [...]
ESMO 2019: Results from ENTRATA clinical trial with telaglenastat plus everolimus for pre-treated kidney cancer
Results from the ENTRATA clinical trial to assess telaglenastat in [...]
European Medicines Agency approves avelumab plus axitinib for first-line treatment of advanced kidney cancer
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines [...]
Tivozanib in heavily pre-treated advanced kidney cancer patients
Further data from the TIVO-3 clinical trial comparing tivozanib with [...]
European Commission approves pembrolizumab plus axitinib combination for first-line treatment of advanced kidney cancer
Based on the findings from the pivotal phase 3 KEYNOTE-426 [...]
